iFabric Corp Updates on Clinical Trial for Treated Medical Scrubs

Rhea-AI Summary

iFabric Corp. has completed phase one of its clinical trial for medical garments treated with ProTX2 antimicrobial and REPELTX water-repellent technologies. Conducted at MemorialCare Medical Group in the U.S., the trial involved 125 nurses wearing three types of scrubs: untreated, treated with ProTX2, and treated with both ProTX2 and REPELTX. The principal goal is to assess bacterial load reduction on treated scrubs compared to untreated ones. The trial transitions to a laboratory phase for bacterial testing, followed by data analysis and submission for peer review.

Positive

• Completion of phase one of clinical trial for treated medical scrubs.
• Trial conducted with a significant sample size of 125 nurses over 375 shifts.
• Promising potential for ProTX2 and REPELTX technologies to enhance infection control in healthcare.

Negative

• None.

MARKHAM, ON / ACCESSWIRE / July 21, 2022 / iFabric Corp. ("iFabric" or the "Company") (TSX:IFA)(OTCQX:IFABF), today provides an update on its clinical trial of medical garments (i.e. "scrubs") treated with the Company's ProTX2 antimicrobial and REPELTX water-repellent technologies.

"I am pleased to report that phase one of our trial has now been completed," said Hylton Karon, President and CEO of iFabric.

"Our trial was conducted at MemorialCare Medical Group - Irvine, in the United States," added Mr. Karon.

"The trial comprised of scrubs supplied in three forms: One treated with our ProTX2 antimicrobial technology, another with a combination of ProTX2 and RepelTX (durable water-repellant technology), and a third (control) group of untreated scrubs. The trial comprised 125 nurses recruited for 3 shifts per nurse, equating to a total of 375 regular staff-shifts. At the start of each shift, nurses were provided new and unmarked scrubs from one of the three groups, which were swabbed twice, once prior to the commencement of the shift and a second time at the end of the shift. The principal endpoint of the trial is to compare bacterial loads on the scrubs treated with our technologies compared to the untreated scrubs. A pathogen load reduction is key to enhancing the protection of the wearer and those with which they encounter during their workday. The spread of infection from surface contact is a major concern in the healthcare industry.

"The trial now moves to it's second, laboratory-based phase, which involves testing for bacterial loads. Once all the laboratory testing is completed, the third step will be to analyze the data under a set of criteria established prior to the trial. The fourth and final step will be providing our analyses to a recognized medical journal for peer review and publishing. Further updates will be provided as the trial progresses through the remaining phases," concluded Hylton Karon.

ABOUT ProTX2

ProTX2® is a powerful eco-friendly technology that provides antibacterial, antimicrobial, antimold, anti-mildew and anti-odour protection. When treated, each textile fiber is fundamentally transformed through PROTX2®'s technology, providing proprietary unrivalled protection against pathogens associated with healthcare-associated infections as well as the toughest odours, for medical and performance textiles.

ABOUT RepelTX:

RepelTX is the next generation in sustainable water repellency performance. RepelTX modifies fabric at the molecular level by permanently attaching hydrophobic ‘hairs' to individual fibers that lift liquids, causing them to bead and roll right off the fabric's surface.

ABOUT iFabric Corp:

Headquartered in Markham, Ontario, iFabric, www.ifabriccorp.com, is listed on the TSX and, currently has 29.7 million shares issued and outstanding. Its two strategic divisions offer a variety of products and services through wholly-owned subsidiaries, namely, Intelligent Fabric Technologies (North America) Inc. ("IFTNA") and Coconut Grove Pads Inc. ("Coconut Grove").

IFTNA is focused on development and sale of high-performance sports apparel, medical protective apparel, consumer protective apparel, and proprietary treatments that provide "intelligent" properties to fabrics, foams, plastics, and numerous other surfaces, thereby improving the safety and well-being of the user. Such intelligent properties include antiviral and antibacterial characteristics, water-repellence and UV protection, among others.

Coconut Grove, operating as Coconut Grove Intimates, is a designer, manufacturer, distributor, licensor and licensee of ladies' intimate apparel products and accessories.

FOR FURTHER INFORMATION, please contact:

Hilton Price, CFO
Tel: 647.465.6161
Email: hilton.price@rogers.com

Investor relations:
Renmark Financial Services
Steve Hosein
Tel: 514.939.3989
Email: shosein@renmarkfinancial.com
Website: www.ifabriccorp.com

SOURCE: iFabric Corp

View source version on accesswire.com:
https://www.accesswire.com/709252/iFabric-Corp-Updates-on-Clinical-Trial-for-Treated-Medical-Scrubs

FAQ

What are the results of iFabric Corp.'s clinical trial for ProTX2 and REPELTX technologies?

The first phase of iFabric Corp.'s clinical trial has been completed, focusing on the effectiveness of treated scrubs in reducing bacterial loads.

When will the next phase of iFabric Corp.'s clinical trial take place?

The next phase, which is laboratory testing for bacterial loads, will commence after the completion of phase one.

What is the primary endpoint of the clinical trial conducted by iFabric Corp.?

The primary endpoint is to compare bacterial loads on scrubs treated with ProTX2 and REPELTX against untreated scrubs to assess pathogen load reduction.

How does ProTX2 technology work in iFabric Corp.'s medical garments?

ProTX2 provides antibacterial, antimicrobial, antimold, and anti-odor protection, transforming textile fibers to combat healthcare-associated infections.

What is the significance of the clinical trial for iFabric Corp.'s business?

Successful results from the trial could lead to enhanced marketability of their medical garments and potentially increase market share in healthcare.